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One of the main problems involved in heart transplantation (HT) is antibody-mediated rejec-
tion (AMR). Many aspects of AMR are still unresolved, including its etiology, diagnosis and
treatment. In this project, we hypothesize that variants in genes involved in B-cell biology in
HT patients can yield diagnostic and prognostic information about AMR.
Methods
Genetic variants in 61 genes related to B-cell biology were analyzed by next generation
sequencing in 46 HT patients, 23 with and 23 without AMR.
Results
We identified 3 single nucleotide polymorphisms in ITGA4 gene (c.1845G>A, c.2633A>G,
and c.2883C>T) that conformed the haplotype AGT-ITGA4. This haplotype is associated
with the development of AMR. Moreover, AMR patients with the haplotype AGT-ITGA4
present lower levels of integrin α-4 in serum samples compared to the reference GAC haplo-
type in control patients.
Conclusion
We can conclude that polymorphisms in genes related to the biology of B-cells could have
an important role in the development of AMR. In fact, the AGT haplotype in ITGA4 gene
could potentially increase the risk of AMR.
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Introduction
The spectrum of clinical rejection in heart transplantation (HT) involves both arms of the
adaptive immune response, the T cell-mediated response leading to cellular rejection (CR),
and the humoral response leading to antibody-mediated rejection (AMR) [1]. The humoral
arm of the immune response is dominated by B-cells and production of antibodies. Adminis-
tration of immunosuppressive agents enables more than 90% of heart transplant patients to
survive longer than a year. However, conventional immunosuppressive agents are more effec-
tive in preventing responses by T cells than responses by B-cells and, therefore, conventional
therapies have little impact on AMR [2]. Thus, the treatment of clinical and subclinical AMR
remains sub-optimal and new approaches are needed to improve it.
The occurrence and severity of AMR are variable, and genetic polymorphisms that affect
the magnitude and nature of the B-cell response are likely to contribute to such phenotypic
variation. In fact, several studies investigated the relationship between single nucleotide poly-
morphisms (SNPs) in genes known to impact B-cell activation/function and antibody effector
function [3,4]. In the field of transplantation, most of these studies were performed in kidney
transplantation and the strongest evidence available suggests that variants affecting the expres-
sion of immunomodulatory cytokines, particularly IL-10, may impact on renal transplant out-
comes [4–7]. To our knowledge, no study has thoroughly examined the relationship of
variants in genes related to B-cell biology and AMR in HT.
We hypothesize that variants in exon-coding sequences and surrounding area of genes
involved in B-cell biology in HT patients can yield diagnostic and prognostic information
about AMR. Thus, identifying variants associated with AMR might allow risk stratification of
patients and a genetic-based immunosuppression regimen.
Materials and methods
Study design and patients characteristics
This is a retrospective case-control study to evaluate a set of 61 genes related to the biology of
B-cells (S1 Fig, S1 Table) and its association with AMR in HT patients from the Advanced
Heart Failure and Transplant Unit of the Complejo Hospitalario Universitario de A Coruña
(CHUAC). The study was carried out on 46 HT recipients, 23 with and 23 without AMR diag-
nosis, who underwent the transplantation between June 2000 and November 2016 [8]. Due to
the different AMR criteria in the last years, in this study the patients before 2013 (n = 15) were
diagnosed as: (1) allograft dysfunction (left ventricular ejection fraction <30% and/or heart
failure), (2) no evidence of other causes of allograft dysfunction (acute cellular rejection or
CAV), (3) evidence of complement activation on endomyocardial biopsy (C4d and/or C3d
staining), and (4) favourable response to therapy addressing AMR (e.g., plasmapheresis, rituxi-
mab, steroid boluses). Whereas AMR in patients who underwent HT after 2013 (n = 8) was
classified according to International Society for Heart and Lung Transplantation (ISHLT) [9].
The categories for the reporting of AMR are as follows [9]: pAMR 0-negative for pathologic
AMR: histopathologic and immunopathologic studies are both negative. pAMR1(H+)-histo-
pathologic AMR alone: histopathologic findings present and immunopathologic findings neg-
ative. pAMR1(I+)-immunopathologic AMR alone: histopathologic findings negative and
immunopathologic findings positive; that is, CD68+ and/or C4d+ for IHC and C4d+ with or
without C3d+ for IF. pAMR2-pathologic AMR: histopathologic and immunopathologic find-
ings are both present. In AMR patients, the inclusion criteria was having at least one positive
endomyocardial biopsy (pAMR1 or higher).
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The 23 AMR cases were matched to 23 controls by gender, age (±5 years), and follow-up
post-transplant. Control patients did not present any distinguishing signs of AMR (pAMR0)
or allograft dysfunction. The study protocol was approved by the local Ethics Committee of
"Investigación de Galicia" (Reference: 2014/012) and the samples were in the “Colección de
muestras para la investigación de insuficiencia cardiaca avanzada y trasplante cardiaco” of the
Instituto de Salud Carlos III (C_0000419, 2012/348). All patients gave written informed con-
sent to participate in the study. The study conforms to the ethical guidelines of the 1975 Decla-
ration of Helsinki.
Genetic study
DNA was extracted from clots and blood samples using QIAamp DNA Blood Mini Kit (Qia-
gen Inc. Hilden, Germany), as previously described [8,10]. In all cases and controls, sequenc-
ing was performed on NextSeq500 using TruSight One Sequencing Panel (Illumina, San
Diego, CA, USA), which included the selected 61 genes related to the biology of B-cells (S1
Table). To assess quality of the NGS data, we define sensitivity as true positive/(true positive
+ false negative), specificity as true negative/(true negative+false positive), and accuracy as
(true positive+true negative)/(true positive+false positive+ false negative+true negative). To
calculate these parameters, direct sequencing of 8 amplicons, containing at least one variant
(S2 Table), was performed as previously described [8,10].
Databases and in silico tools used
The potential effect of SNPs associated with the presence or absence of AMR was predicted
using in silico tools as previously described [8]. Moreover, the minor allele frequency (MAF) of
the SNPs detected by NGS was extracted from Single Nucleotide Polymorphism Database
(dbSNP) and/or The Exome Aggregation Consortium (ExAC).
Localization of variants
Topological placement of the mutations was done using the Swissprot database (http://ca.
expasy.org/uniprot/). The Uniprot database provides generally accepted residue ranges corre-
sponding with each domain region and specialized subregion.
Predicting damaging amino acid substitution
Five online tools were used to predict the pathogenicity of the missense variants: SIFT [11]
(http://sift.jcvi.org/www/SIFT_seq_submit2.html), Polyphen-2 [12] (http://genetics.bwh.
harvard.edu/pph2/), PhDSNP [13] (http://snps.uib.es/phd-snp/phdsnp.html), SNAP2 [14]
(https://www.rostlab.org/services/snap/), and MutationTaster [15] (http://www.
mutationtaster.org).
Predicting splice site variants
We evaluated the effect of synonymous variants in the vicinity (±6 pb) of the splice site, includ-
ing splice site modification and splice-enhancing sequences, using 5 tools: GeneSplicer [16]
(http://www.cbcb.umd.edu/software/GeneSplicer/), NetGene2 [17] (http://www.cbs.dtu.dk/
services/NetGene2/), ESEfinder 3.0 [18] (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.
cgi), SSP [19] (http://www.fruitfly.org/seq_tools/splice.html), and HSF [20] (http://www.umd.
be/HSF/).
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Enzyme-Linked Immunosorbent Assay (ELISA) measurements
Pre-transplant serum samples were used for the determination of functional ITGA4 (n = 16)
levels, using a commercially available competitive sandwich ELISA kits (ITGA4 ELISA Kit
(Human) (OKEH01078) from Aviva Systems Biology (San Diego, USA)).
ITGA4 measurable concentration range was between 0.156 to 10 ng/mL. Serum samples
were measured in duplicate without making any dilution. The absorbance at 450 nm was mea-
sured in a spectrophotometer.
Statistical analyses
Genotype frequencies were tested by multiple inheritance models (codominant, dominant,
recessive, log-additive) using SNPStats software [21] and the association function of R soft-
ware. When these models showed a significant association, McNemar’s chi-square test was
performed with R. Moreover, a haplotype association analysis for SNPs described in the same
gene was also realized with SNPStats and THESIAS program [22] (http://genecanvas.ecgene.
net). In all analysis, P-values�0.05 were considered to indicate statistical significance.
Results
Quality of the NGS data
The mean coverage over all the genes related to the biology of B-cells studied was 73.5±3.6 fold
(Fig 1A). Base calling accuracy, measured by the Phred quality score (Q score), indicates the
probability that a given base is called incorrectly by the sequencer. The runs in the NextSeq500
platform showed a Q score > 30, which means a probability of an incorrect base call of 1 in
1000 reads and a base call accuracy 99.9%, in 80.6±2.6% of reads. The range of bases with Q30
score showed in percentage was 75–90% including the five runs performed.
To determine the accuracy, specificity, and sensitivity of the NGS protocol, we directly
sequenced 8 selected amplicons containing at least one variant detected by NGS in 13 samples.
From 6094 readable bases in the Sanger sequencing, we observed 6067 true negative calls and
27 true positive calls. No false positive or false negative calls were found, together resulting in a
sensitivity, specificity, and accuracy of 100%.
Genotype association to AMR
The AMR patients included in the study, n = 23, and their paired control patients, n = 23, pre-
sented the clinical characteristics summarized in Table 1. Fifteen AMR patients diagnosed
before 2013 presented the clinical and pathological evidence described in methods section,
whereas patients diagnosed after 2013 were classified as: 4 pAMR(I+) and 4 pAMR2.
After sequencing the whole coding region and the flanking intronic region of 61 genes, we
examined the frequency of 285 polymorphisms found in 23 AMR cases and/or in 23 controls
(Fig 1B, S3 Table). We found statistically significant differences, after SNPStats and McNemar
analysis, in the genotypes of 3 SNPs in the ITGA4 gene: c.1845G>A, c.2633A>G, and
c.2883C>T (Table 2). For c.1845G>ASNP in ITGA4, the greatest significance was achieved
for a dominant model where A-mutant alleles in homozygotes or heterozygotes (AA/AG) had
increased odds of developing AMR compared to the GG homozygotic wild type [p = 0.002;
odds ratio (OR) = 7.4; 95% confidence interval1.9–28.9;Table 2]. Moreover, a higher frequency
of the A allele in AMR patients was confirmed in the codominant, recessive, and Log-additive
model as well as in the McNemar test. For the second ITGA4 SNP,c.2633A>G, the lowest P-
value was obtained after applying the dominant model where G-mutant alleles in homozygotes
or heterozygotes (GG/AG) had increased odds of developing AMR compared to the AA
ITGA4 variants in AMR
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Fig 1. A, Sequence coverage. Graph representing the sequence coverage of the genes related to the complement cascade analysed in the study.
Over all, mean coverage of the genes studied was 73,5±3,6. B, SNPs distribution per gene. Bar graph showing the distribution of SNPs per gene in
AMR (A) and control patients (B).
https://doi.org/10.1371/journal.pone.0219345.g001
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homozygotic wild type (p<0.001; OR = 9.7; 95% CI 2,4–39.6;Table 2). Additionally, a higher
frequency of the G allele in AMR patients was confirmed in the codominant, recessive, over-
dominant and Log-additive model as well as in the McNemar test. Finally, for the third ITGA4
SNP,c.2883C>T, the most significant P-value was obtained after applying the dominant
model where T-mutant alleles in homozygotes or heterozygotes (TT/CT) had increased odds
of developing AMR compared to the CC homozygotic wild type (p = 0.002; OR = 7.4; 95% CI
1.9–28.4; Table 2). In addition, a higher frequency of the T allele in AMR patients was con-
firmed in the codominant and Log-additive model as well as in the McNemar test.
A haplotype association analysis for these 3 SNPs in each subpopulation was then per-
formed (S4 Table). The four observed haplotypes were analyzed: 1.) c.1845G-c.2633A-c.2883C
haplotype (GAC); 2.) c.1845A-c.2633G-c.2883T haplotype (AGT), which is a variant with
minor allele frequency in the 3 SNPs; 3.) c.1845A-c.2633A-c.2883T haplotype (AAT); and 4.)
and c.1845G-c.2633A-c.2883T haplotype (GAT). We found differences in haplotype frequen-
cies to be statistically significant for AGT haplotype (p = 0.005 in SNPstats and p<0.001 in
THESIAS) being more frequent in cases (41.3%) than in controls (12.4%). Furthermore, haplo-
type analysis suggests that the AGT haplotype is associated with the development of AMR with
Table 1. Clinical characteristics of the patients included in the study.
Variable AMR (n = 23 patients) Control (n = 23 patients) p-value
Age±sd (years) 50.2±16.5 50.0±15.9 0.8
Male 87.0%(20) 87.0%(20) 1.0
Female 13.0%(3) 13.0%(3)
Primary heart disease
Dilated cardiomyopathy 26.1%(6) 43.5%(10) 0.4
Ischemic cardiomyopathy 52.2%(12) 26.1%(6)
Valvular cardiomyopathy 8.7%(2) 13.0%(3)
Others 13.0%(3) 17.4%(4)
Follow-up (years)
<2 years 17.39%(4) 4.35%(1) 0.2
2–5 years 30.43%(7) 17.39%(4)
�6 years 52.17%(12) 78.26%(18)
Time to AMR diagnosis after transplant (years) 3.5±0.6




Steroids 100%(23) 100%(23) 0.9










� pAMR classification only available for patients who underwent HT after 2013 (n = 8).
https://doi.org/10.1371/journal.pone.0219345.t001
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an OR of 11.0 (95% CI 2.3–53.6) and 7.3 (95% CI 2.5–21.3) in SNPstats and THESIAS
respectively.
In silico analysis of ITGA4 variants associated with the presence or absence
of AMR in genes related to B-cell biology
Although all the variants associated with the presence or absence of AMR in genes related to
B-cell biology found in this study were polymorphisms previously known, we used several in
silico software in order to predict an impact on the function of the protein (Table 3).
Table 2. Statistical analysis of 3 variants in ITGA4 gene in control and AMR groups.
SNP Model Genotype Control AMR OR (95% CI) p-value AIC
c.1845G>A R (F(x) association) Codominant G/G 14 (60.9%) 4 (17.4%) 1.0 0.003 58.0
G/A 8 (34.8%) 12 (52.2%) 5.2 (1.3–21.9)
A/A 1 (4.3%) 7 (30.4%) 24.5 (2.3–262.5)
Dominant G/G 14 (60.9%) 4 (17.4%) 1.0 0.002 58.2
G/A-A/A 9 (39.1%) 19 (82.6%) 7.4 (1.9–28.9)
Recessive G/G-G/A 22 (95.7%) 16 (69.6%) 1.0 0.01 61.0
A/A 1 (4.3%) 7 (30.4%) 9.6 (1.1–86.2)
Overdominant G/G-A/A 15 (65.2%) 11 (47.8%) 1.0 0.2 66.0
G/A 8 (34.8%) 12 (52.2%) 2.0 (0.6–6.7)
Log-additive — — — 5.06 (1.74–14.70) <0.001 56.0
McNemar test McNemar Chi squared equals 5.79 with 1 degrees of freedom 0.02
c.2633A>G R (F(x) association) Codominant A/A 17 (81.0%) 7 (30.4%) 1.0 0.001 53.5
A/G 4 (19.0%) 13 (56.5%) 7.9 (1.9–32.8)
G/G 0 (0%) 3 (13.0%) 0.0
Dominant A/A 17 (81.0%) 7 (30.4%) 1.0 0.001 53.0
A/G-G/G 4 (19.0%) 16 (69.6%) 9.7 (2.4–39.6)
Recessive A/A-A/G 21 (100%) 20 (87.0%) 1.0 0.2 60.8
G/G 0 (0%) 3 (13.0%) 0.0
Overdominant A/A-G/G 17 (81.0%) 10 (43.5%) 1.0 0.009 58.1
A/G 4 (19.0%) 13 (56.5%) 5.5 (1.4–21.7)
Log-additive — — — 8.6 (2.2–33.3) 0.001 51.7
McNemar test McNemar Chi squared equals 5.26 with 1 degrees of freedom 0.02
c.2883C>T R (F(x) association) Codominant C/C 14 (60.9%) 4 (17.4%) 1.0 0.006 59.6
C/T 7 (30.4%) 12 (52.2%) 6.0 (1.4–25.6)
T/T 2 (8.7%) 7 (30.4%) 12.2 (1.8–84.0)
Dominant C/C 14 (60.9%) 4 (17.4%) 1.0 0.002 58.2
C/T-T/T 9 (39.1%) 19 (82.6%) 7.4 (1.9–28.9)
Recessive C/C-C/T 21 (91.3%) 16 (69.6%) 1.0 0.06 64.1
T/T 2 (8.7%) 7 (30.4%) 4.6 (0.8–25.2)
Overdominant C/C-T/T 16 (69.6%) 11 (47.8%) 1.0 0.1 65.5
C/T 7 (30.4%) 12 (52.2%) 2.5 (0.7–8.3)
Log-additive — — — 3.9 (1.5–10.4) 0.002 58.2
McNemar test McNemar Chi squared equals 9.39 with 1 degrees of freedom 0.002
https://doi.org/10.1371/journal.pone.0219345.t002
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The missense polymorphism (p.Gln878Arg-ITGA4) does not seem to alter the function of the
protein (Table 3). In the case of synonymous polymorphisms in the vicinity of splice site
(Table 3), we used the Houdayer et al criteria of a decrease of at least 20% in the score of the pre-
dictions made to consider a possible effect on the splicing process [23]. Only the variant p.
His961(p=) in ITGA4 gene was predicted to have a possible impact on the corresponding natural
splice site, by 3 out of 5 software used. However, the synonymous variant p.Thr615(p=) could
modify the exonic splicing enhancer, and thus, it could have an impact in protein expression.
Serum integrin α-4 levels in AMR transplant patients with ITGA4-AGT
haplotype
The median integrin α-4 serum level measured before transplantation in 8 AMR patients that
carried the AGT haplotype was 0.02 ng/mL ([IQR] 0.00–0.1 ng/mL) (Fig 2). This value is sig-
nificant lower (p<0.05) compared to the median integrin α-4 serum level measured before
transplantation in 8 patients who did not present with AMR and in whom the analyzed haplo-
type was not present (0.1 ng/mL; [IQR] 0.05–0.7 ng/mL).
Discussion
The present data represents the first study on the effect of variants on genes involved in the B-
cell biology related to AMR in HT patients to date. We have identified three SNPs in ITGA4
Fig 2. ITGA4 gene. Schematic structure of the human ITGA4 gene and primary protein domains of ITGA4 showing relative position of the 3 common polymorphism
found (c.1845G>A), c.2633A>G), c.2883C>T). ITGA4 serum levels according to ITGA4 haplotype among 8 AMR patients (AGT) and 8 control patients (GAC).
https://doi.org/10.1371/journal.pone.0219345.g002
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gene [p.Thr615(p=), p.Gln878Arg, and p.His961(p=)], which correlates with the development
of AMR. These 3 SNPs conform a haplotype: AGT-ITGA4, which could be associated with
development of AMR in HT patients. Our data showed that the AGT haplotype in ITGA4 gene
in AMR patients present lower levels of integrin α-4 in serum samples compared to the refer-
ence GAC haplotype in control patients. In the past decade, efforts to understand how an indi-
vidual´s genetic can impact on disease susceptibility, severity and responses to treatment have
progressed rapidly and the AGT haplotype described in this study could open a new approach
to AMR.
Cell adhesion is critical in immune system function, and α4 integrin (also named as CD49d
or VLA4), encoded by ITGA4 gene, plays a particularly prominent role in the immune system
through its adhesive and signalling functions [24]. These functions include immune cell traf-
ficking, activation of myeloid cells and naïve T and B lymphocytes, differentiation of effector T
cells into Th1, Th2, or Th16, immunological synapse and binding of α4 integrin provides cost-
imulatory signals to T cells [25]. Moreover, α4 integrin mediates B-cell localization in the bone
marrow and in germinal centers of secondary lymphoid organs. α4 integrin is also involved in
survival signalling pathway that inhibits apoptosis of germinal center B-cells through the up-
regulation of the antiapoptotic B-cell lymphoma gene family member, Bcl-XL [24]. The promi-
nent role of integrins in the immune system is also demonstrated because they have been
implicated in the pathogenesis of several autoimmune and inflammatory diseases, including
asthma, multiple sclerosis, contact hypersensitivity, rheumatoid arthritis, and Crohn´s disease
[26–29].
In the field of transplantation, most of the studies focus on integrins were done in CR due
to their role in T-cells. It has been described that αvβ6, which belong to another family of integ-
rins but with similar functions to α4 integrin, are increased in acute CR of heart allograft and
cardiac allograft vasculopathy in humans [30,31]. In two models of rat kidney transplantation,
αv integrin antagonist was able to significantly ameliorate the infiltration of CD8+ T cells and
macrophages into the graft and inhibit proliferation of mononuclear cells and fibroblasts in
the interstitium of kidney allografts [32]. Treatment with anti-α4 antibody in islet allografts
prolongs graft survival, suggesting that the α4 adhesion system may be important in antigen-
presentation, T cell activation and lymphocyte recruitment to the graft [33]. Moreover, previ-
ous studies have demonstrated that anti-α4 integrin antibody treatment prolongs, but not
indefinitely, the survival of cardiac allografts in animal models [34,35].
Our study is the first analysis of ITGA4 genotype and α4 integrin expression focus on AMR
patients. In our cohort, the haplotype AGT present a higher frequency in patients with AMR
and it is associated with lower serum levels of α4 integrin. To explain a possible role of α4
integrin in AMR, we have to take into account that α4 integrin are expressed at higher levels
by B-cell precursors than mature B-cells [36]. Thus, we can speculate that our lower serum lev-
els in AMR patients could be due the presence of less B-cell precursors and more mature B-
cells and these mature B-cells would secrete antibodies that bind to antigens and activate com-
plement, responsible for the AMR [37]. Moreover, Weinländer et al described that inhibition
of endothelial cell spreading and migration by inflammatory cytokines is mediated by human
guanylate binding protein-1 (GBP-1) through induction of ITGA4 expression [38]. Thus, a
down regulation of ITGA4 gene could have an impact in GBP1 induction, which in turn may
result in a higher endothelial cell proliferation and migration during AMR. Furthermore, a
down-regulation of the ITGA4 gene has also been described in other diseases, such as Crohn´s
disease [39] or the first stages of B-cell chronic lymphocytic leukemia [40]. Interestingly, in the
same line as our haplotype decreases the expression of ITGA4, 2 different SNPs (rs7023923
and rs6740847) downregulate ITGA4 expression (Maugeri et al 2011). However, more
research must be done to validate this hypothesis and the role of the AGT haplotype in AMR.
ITGA4 variants in AMR
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If so, these results can open a new approach of the prevention of AMR because natalizumab, a
humanized monoclonal antibody against the cell adhesion molecule α4-integrin approved by
FDA for multiple sclerosis and Crohn’s disease, could be a candidate therapy for preventing
AMR.
Limitations
The current study presents some limitations including a retrospective design, a relatively small
sample size, and an evolving criteria of AMR definition. However, we believe that this study
opens a new pathway of understanding that variants in genes related to the B cell biology may
influence the development of AMR, a field not yet explored.
Conclusions
The main results of this study are: 1.) AGT haplotype is associated with the development of
AMR and 2.) integrin α-4 serum levels in patients carried AGT haplotype are lower that
patients carried the reference GAC haplotype. Thus, polymorphisms in the genes related to the
biology of B-cells could have an important role in the development of AMR in cardiac trans-
plants. Specifically, the AGT haplotype in ITGA4 gene could increase the risk of AMR. How-
ever, the detailed molecular mechanisms on how this haplotype exerts effects in the immune
response leading to AMR are unclear and more research must be done to assess its role.
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